CN104263699A - Culture method for large-scale preparation of clinical treatment level dermal multipotent stem cells for cell transplantation - Google Patents
Culture method for large-scale preparation of clinical treatment level dermal multipotent stem cells for cell transplantation Download PDFInfo
- Publication number
- CN104263699A CN104263699A CN201410482325.8A CN201410482325A CN104263699A CN 104263699 A CN104263699 A CN 104263699A CN 201410482325 A CN201410482325 A CN 201410482325A CN 104263699 A CN104263699 A CN 104263699A
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- skin
- stem cells
- dermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a culture, screening and amplification technology of clinical treatment level dermal multipotent stem cells. These bottlenecks are always hot and difficult problems of research in the field of biological stem cells; at present, separation and purification are carried out by using the remarkable adhesion characteristic of a basement membrane, and the clinical treatment level dermal multipotent stem cells are obtained by adopting a three-dimensional culture and amplification means. The technology is applicable to the screening and separation of a target cell level by depending on amplifying adherent type cells and providing a three-dimensional high-simulation in-vivo extracellular matrix system. The technology is a novel biological cell culture technology, and adult (embryo skin) stem cells are subjected to in-vitro culture in a high-simulation in-vivo attached environment. The environment where a high-simulation substrate is located adheres, screens and cultures target dermal multipotent stem cells, so that the passage capability is high, the multiplication capacity is high, and a differentiated full-thickness dermal structure can be formed in an in-vitro environment. Immunogenic cells are screened out, so that immunologic escape is safely obtained, the transplantation time is prolonged, the clinical application of tissue engineering is improved, the healing of a surface of wound is promoted, and a clinical treatment level cellular solving scheme with absolute advantages is provided for skin diseases.
Description
One, technical field:
The invention belongs to biological stem cells technology, field of tissue engineering technology.Relate in a kind of external structure height analogue body and attach environment separation screening, the cultivation of skin progenitor cell, amplification technique.Acquisition clinical treatment level dermal multipotent stem cells is applied to the active seed stem cell in organization engineering skin constructing technology.
Two, background technology introduction:
Skin is the maximum organ of human body, participate in resisting biotic intrusion, ultraviolet radiation and prevent loss of moist, regulate body temperature maintains the aspects such as individual appearance and plays very important physiological action, it is the important part that human immune system forms, and skin cells is the elementary cell forming this organ, skin cells fundamental research field is the important research approach disclosing skin health, growth, prevention, treatment.
Extracellular matrix (extracellular matrix, ECM) is extensively present in the basic filling component in intercellular substance, is cell metabolism, growth, breeding, differentiation, expression, transmission, reciprocal relied on place of crucial importance.Early stage researcher thinks. epimatrix is a kind ofly organize interior, extracellular simple underwork.Hauschka and Konigsberg finds the collagen of filling tissue space research in 1966 and promotes that sarcoplast transforms the phenomenon of myotube.And after the two years, proved that scholars have just had new Cognize and Ponder to this stable outer material microenvironment.
Hay reported ECM and has important inducing action to embryo development procedure after 11 years.The phenomenon that ECM affects cell behavior is paid close attention to and is studied widely, but the substantial connection of not shaping theoretical basis evidence ECM and cell.Until nineteen eighty-two has scholar to bring forward proof and sets up ECM and the model of " dynamically reciprocal " between cytoskeleton and nuclear matrix.In this mould, ECM molecule and cell surface receptor interact, and then signal are entered in cytoplasm by cytolemma conduction, cause from cytoskeleton to nuclear a series of change, cause the expression of some specific gene.
And prove that the expression product of these genes can be had an effect to ECM again conversely, many researchs of today confirm the reasonableness of this model, and prove cell and ECM interact participated in the sticking of cell directly, grow, migration, differentiation and procedural extremely (apoptosis) process; Epimatrix participates in the activity regulating cytokine, somatomedin; Can also directly activate, signal transduction mechanism in active cell.Due to this adjustment to cell and the conduction to signal.Therefore, we must fully understand the chemistry of extracellular matrix, physics, biological property and function and in the formation of tissue and the effect in repairing, could apply these biomaterials better and be configured to tissue acceptance, and even simulated tissue improves " the biological framework " of regeneration.What the height that we set up intended that cell epimatrix material utilizes is just reverse theory, and instruct the understanding that we carry out in a deep going way ECM, also retroaction obtains our available stem cell simultaneously, and this research mode promotes that subject moves ahead and develops.
Skin progenitor cell content in normal skin tissue is few, and it is that one has unlimited updating ability in vivo that stem cell is generally acknowledged, and can be differentiated to form corresponding holostrome tissue differentiation cell, and vitro culture has long term growth potential and can form unlimited clone.The wound healing surface of a wound, the important participant of skin renewal metabolism regeneration.But owing to lacking desirable screening method at present, stem cell is screened and authentication method report less.
Three, skin progenitor cell title general introduction
Within 1981, Potten proposes, skin progenitor cell (skin stem cell).Epidermal stem cells (epidermal sten cell, ESC) or keratinocyte stem cell (Keratinocyte stem cell, KSC); Corium stem cell (dermis stem cell) or dermal multipotent stem cells (dermal multipotent sten cell) or be called skin precursor cell (skin-derived precursor).
Corium mesenchymal cell is dermal multipotent stem cells again, derives from and grows early stage mesoderm and ectoderm, have differentiation potential widely, can break up to the histocyte of multiple mesoderm and ectodermal origin.Discovered in recent years, this kind of cell is extensively present in ripe individual Various Tissues, and has confirmed to ask that mesenchymal stem cells is present in the tissues such as marrow, muscle, brain, periosteum.The various kinds of cell such as neurone, nerve fiber, muscle, fat can be divided into when dermal multipotent stem cells is cultivated in vitro.
Dermal multipotent stem cells is present in skin corium.Its comparatively small amt, Peripheral blood is for good, and nutritious, residing microenvironment has superiority; Can breed under the factors such as damage or growth-stimulating, there is slow periodicity; There is the feature of undifferentiated cell; Self multiplication capacity is strong; Body outer clone ability is outstanding waits predominant cell feature.Important healing dryness cell is rebuild in the regeneration of trauma repair.
Four, dermal multipotent stem cells general introduction
In corium, the research of multipotential stem cell is started late, and the biology understanding for it just just starts at present, thus the current not yet unified definition of dermal multipotent stem cells.But present result of study confirms, the dermal multipotent stem cells of this source for mesenchymal stem cells participates in the renewable reservoir process of skin in adult. and the microenvironment caused after skin wound has certain regulating and controlling effect to dermal multipotent stem cells, this may be because after wound, the local skin factor changes, facilitate the migration and differentiation of dermal multipotent stem cells, thus accelerate the reparation of wound.Thus, someone infers that the interaction between stem cell and microenvironment is the physiological foundation (.Shi etc. such as Watt, Van, history spring dream, 2004) that it participates in repairing.In corium, multipotential stem cell can be used as the derived cell of dermis restoration cell, has distribution, but it be unclear that in intradermal concrete location it at present in the corium of hair follicle and non-hair follicle.But increasing experimental result shows, in the hair papilla and dermal sheath of hair follicle, have the adult stem cell of the Clonal growth of tool to distribute, these cells have certain differentiation potential, and in hair papilla, be rich in more dermal multipotent stem cells (Jahoda etc., 2003; The .2005 such as Legue).
Because dermal multipotent stem cells is easy to obtain relatively, Multidirectional Differentiation can be carried out, thus it there are wide basis and clinical study prospect in autologous stem cells gene therapy simultaneously.
Five, the feature of dermal multipotent stem cells
The result of study of Toma etc. shows, utilizing interpolation Urogastron (EGF) to carry out vitro culture with the nutrient solution of Prostatropin (bFGF) to being separated the dermal multipotent stem cells obtained, can form spherical clone.Current data display, dermal multipotent stem cells can carry out amplification cultivation in vitro, and can pass 20 generations more than, has strong multiplication capacity.A large amount of experimental result display: TGF-β suppresses the propagation of skin base layer keratinocyte, but can promote fibroblastic growing multiplication.The research such as Yoko confirms to add TGF-β in the vitro culture of dermal multipotent stem cells, ensureing under the prerequisite that cell characteristics is stable, can promote the propagation of dermal multipotent stem cells further, TGF-β tool in the breeding of dermal multipotent stem cells has certain effect.
Cultivate in the induction system of adding certain factor (as dexamethasone, vitamins C, tretinoin etc.), dermal multipotent stem cells can break up to bone like cell, osteoblast-like cells, fat-like cell, neural-like cells, there is multi-lineage potential (Dyce etc., 2004).After the dermal multipotent stem cells in rats of separation is cultivated amplification by Gorio etc. in vitro, then autotransplantation enters the cell observing transplanting in impaired notochord after .60 ~ 90d and still survives, and is divided into the cell with spongiocyte and neuronal cell marker molecule.Result of study shows, dermal multipotent stem cells may have heterogeneity, containing a class small volume but the more original cell mass of function, people utilize method for gene chip to detect, and dermal multipotent stem cells expresses the specific transcription factor of multiple different cell type, comprise osteocyte, neurocyte, muscle etc., this may be the molecular basis of its multi-lineage potential.
Six, the separation of dermal multipotent stem cells and discriminating
The method of the adherent screening of the many employings of dermal multipotent stem cells is separated, utilizes this method simultaneously and combine the several respects such as relatively special mark molecule, proliferation activity, differentiation potential and dermal multipotent stem cells is identified.
Normal according to specific surfaces molecule marker with unlimited upgrade feature with presence or absence of differentiation capability and differentiate stem cell at present.Now special surface marker is not found to the research of dermal multipotent stem cells, but it can express the surface moleculars such as CD90, CD59, CD44, nes-tin can be expressed particularly in dermal multipotent stem cells, and do not express vimentin with dermal fibroblast unlike it, yet collagen-free secreting function.
Dermal multipotent stem cells have hair-fields and without the corium of hair-fields in all have distribution.History spring dreams etc. pass through the Attachment culture dermal multipotent stem cells of rat and people's foreskin, show multipotency differentiation potential, can to scleroblast and Adipocyte Differentiation through induction.In recent years, foreign scholar also by stem cell media, the separation and Culture human body dermal multipotent stem cells clone of Different age group; Clone's number that it is cultivated in vitro, the size of multiplication capacity and its differentiation capability, by the impact at age.Though at the early-stage to the research of dermal multipotent stem cells at present, there are some researches show that it has potential application prospect in organizational project, gene therapy and cell therapy etc.
Seven, traditional method for sieving introduction
Because skin progenitor cell has stronger adhesivity to basilar membrane, more faster than other cell type to the adhesion speed of cell extracellular matrix, so utilize this kind of characteristic to carry out cultivation screening.Skin progenitor cell screening traditional is at present following sets forth:
Method one (3T3 trophoderm method): the historical background in a human skin cell vitro culture research existing century, set up amplification in vitro culture system in the fibroblast strain 3T3 trophocyte of 3TS-J2 mice embryonic knurl designed by scholar Rheinwald and Green in 1975, and irradiate by gamma-rays lethal dose, prevent stem cell to be subject to the impact of heterologous species.Deactivation 3T3 trophocyte can promote the attaching that skin cells screens and growth as cultivating the trophoderm of skin cells, and has not by the function of inhibition contact fibroblastic growth proved.Each subbreed that selected by laboratory, function is more stable but the misgivings can't got rid of completely it, also need to continue observe and explore effective alternative method.Although Green study this method 3T3 it be an xenogenesis there is the cell of asking change nature, have many laboratories once to attempt to be replaced with other measures, up to now, its effect is still the most effective in various method, continues to be widely used.From the 1st routine clinical application to nearly 30 years of order, not yet find the adverse consequences caused because of it.
Method two (Fibrinogen and thrombin substrate method): Graziella P scholar's research Fibrinogen and zymoplasm are as matrix separate skin cell;
Method three (IV Collagen Type VI sticks method): Jone PH etc. utilize aforesaid method from adult foreskin or cadaver skin through digestion, IV Collagen Type VI is utilized to do substrates separate skin cell, selected substrate is xenogenesis collagen, there is the possibility of pollution of different genera, and substrate is expensive, be not suitable for industrialized scale or long-term cultivation, be applicable to tentative low dose research;
Method four (flow cytometer sieve method): scholar Van Rossum MMj and Kaur P etc. obtains epithelial cells from people's fritter biopsy, utilize integrin to mark different in nature mark and utilize flow cytometric sorting stem cell, selecting method is complicated and technical requirements is high, substantially apply integrin β 1, cell adhesion molecule CD49, add the multiple marks such as cell nuclear antigen (PCNA) and carry out character separation, although stem cell is screened, but marker label retaining stem cell can be left cannot effectively remove, exist and whether affect stem cells hyperplasia, differentiation, variability etc.This method is applicable to Marker Identification and measures stem cell, and is not suitable for the stem cell enrichment method of clinical application;
Method five (xenogenesis becomes fiber suspension sieve method): scholar Hagar B utilizes DMEM, low calcium ion mouse fibroblast cell conditioned medium as substratum, without trophocyte.But having research report epidermal stem cells and basilar membrane to depart to bring out and enter the differentiation cycle, be divided into transitional expansion cell, is likely maintain the possible condition that skin cells controls differentiation characteristic according to the high-adhesiveness guessing skin cells and basilar membrane.If so do not utilize trophoderm, likely in long-term cultivation process, skin cell differentiation causes the uncontrollable development of follow-up study;
Method six (consubstantiality becomes fiber to attach sieve method): scholar's banket etc. utilize with reference to improving scholar Hagar B and Dunnwald mouse fibroblast cell, make into donor in advance amplification in vitro inoblast for attachment substrate as trophoderm, cultivate consubstantiality skin cells, but patent is the clear and definite detailed step how preparing trophoderm plate not, the paving ware cycle is short, become the adherent power of fiber low, screen repeatedly PBS clean purge process can lose part cultivate target attach successful inoblast, thus reduce the yield of targeted stem cells, skin cells has the same originality of consubstantiality in theory, another technical problem is, two kinds of cells should consider the complicacy of nutrient solution in total same culture environment, the phenomenons such as emulative growing multiplication suppression may be there is in two kinds of cells, there is technical difficulty in later separation skin cells, common methods in existing six can not be better than, advise that it can make compound into this method and add other and cover effective other the larger screening thing of behavior that sticks of ware with increasing target cell yield, or deactivation becomes fiber lay down ware confluent monolayer cells.
Method seven (methylcellulose gum culture dish attaches sieve method): foreign scholar utilizes interpolation methylcellulose gum, carries out dermal multipotent stem cells cultivation with the DMEN/F12 containing 2%B27.Methylcellulose gum is easily corrupt by microbial destruction, and the method is prepared culture medium solution viscosity and strengthened and be unfavorable for that cell freely stretches amplification.The integration material affected between flanking cell exchanges as nutritive substance, gaseous interchange etc., many uncertain unfavorable factors.And this inorganic materials, not by body Absorption And Metabolism, introduces not easy-clear in culturing process, be unsuitable for the requirement of clinical treatment level cell.
In sum, dermal multipotent stem cells extracellular matrix stick strong rapid charater, it is fast-developing that human dermis's multipotential stem cell that in-vitro screening is cultivated is able to method specificity at home and abroad.And dermal multipotent stem cells biology performance, can accomplish that promoting function, the present invention avoids potential deleterious gene and pollute dermal multipotent stem cells, all have the important directive significance do not replaced of period of history in basic scientific research, clinical treatment, stem-cell research direction, skin regeneration injury repairing, the high structure intending organization engineering skin etc.
Eight, organization engineering skin background introduction
It is that work starts from this century (Harrison 1907, Carrel 1912) that regenerating tissues engineering cell is set up, and instructs and leads biology, each large linking fields such as clinical medicine material, becomes one of important basic science.Tissue construction and cell injuring model are vital problems.Get tissue from donor donor live body, the serial specific micro-environment in vitro system such as physiological environment in analogue body, carry out hatching and cultivate, make histocyte healthy growth.
Organization engineering skin is set up to be applied in early days and is repaired burn and ulcer and other skin injury field, and the Yannas I.V. of John F.Burke and the MIT of Massachusetts General Hospital cooperates, and prepares artificial skin surrogate first.But this artificial skin surrogate is not relevant to cytobiology, is under the jurisdiction of scaffold materials of tissue-engineered skin category.Along with the basic subject of cytobiology develops, people start to integrate two large subjects, collaborate solves trauma skin reparation and builds, and real has cooperated at the Eugenen Bellhe of Ha Fu university Honward Green and MIT containing active cells organization engineering skin.Early stage customization dermatoplasty treatment achieves biology medical science and to be situated between concern of attracting attention.
Phase early 1980s timbering material is by FDA license listing, the composite skin graft material be made up of collagen grid is continuously created, internal layer is that bovine collagen and chondroitin sulfate are formed, skin is silica column, after surface of a wound transplanting, internal layer contacts with the surface of a wound and is slowly degraded, after several weeks, silicone layer removes, and covers autotransplantation skin after debridement, and coverture is accepted by clinical.
The scientist Bellhe of MIT creates organization engineering skin materialogy and biology perfect adaptation and establishes first hand organizational project regeneration company (Organogenesis Inc) in the world, is the model of scientific circles businessman.This active mass of family engineering skin pioneer leads company to remain in one of the highest tissue engineering companies of artificial skin share of market.
The TransCyte produced by Advanced Bionhealing company by first tissue engineering product of U.S. FDA approval listing for 1997.For burn wound repairing and treating.This product belongs to the fibrocyte of collagen as tissue engineering scaffold plantation deactivation, becomes business-like first " allosome non-activity cellular system engineering corium therapy ".The Apligraf that Dermagraft and Integra and Organogenesis Inc manufactures also obtains FDA approval, utilize neonatal foreskin through biology vitro culture active cells, the organization engineering skin of preparation, for ulcerous skin and large-area burns regenerative therapy.This product stricti jurise has class skin tissue engineering artificial skin, contains active 4 ~ 8 cells gone down to posterity and have integral skin dermal cell to be structured in degradable holostrome artificial skin on tissue engineering bracket.And part is rejected and is reduced Langerhans cell, reduce the immunological rejection of acceptor, the dead cell of non-activity is absorbed by the surface of a wound through the effect of wound tissue liquid and the relevant humoral factor metabolism small molecule segment basal nutrient healing substances that can be used for wound repair that is decomposed.This product is made and is placed on-70 DEG C of preservations, and 37 DEG C of recoveries rapidly, have the active cells of 50% to have activity after recovery, active maintenance posts to the medical department of specifying in 5 days by express delivery.
The market access of these products has led the brand-new regenerative medicine organization engineering skin epoch to start.
Based on tissue engineering artificial skin present situation both at home and abroad, set up organization engineering skin stem cell-Gao and intend cells in vivo epimatrix, the first holostrome tissue engineering artificial skin industrialization product containing epidermal stem cells and dermal multipotent stem cells of matrix attachment in-vitro screening method design.
Summary of the invention
1. one kind is combined for the substratum screening and cultivate dermal multipotent stem cells,
Preparation nutrient solution A: inactivated fetal bovine serum 40 ~ 60ml, Transferrins,iron complexes 5 ~ 15 μ g/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, vitamins C 1 ~ 3 μ g/ml, Regular Insulin 2 ~ 4ug/ml, cholera mycin 2.5 ~ 4.5u/L, vitamins C 1 ~ 3 μ g/ml, EGF5 ~ 25ng/ml, hydrocortisone 0.4 μ g/ml, commercial substratum DMEM/F12 (3: 1) constant volume are to 500ml.
Preparation nutrient solution B: inactivated fetal bovine serum 80ml, Transferrins,iron complexes 6 ~ 17 μ g/ml, adenosine 10 ~ 25mg/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, cholera mycin 2.5 ~ 3.5u/L, Regular Insulin 4 ~ 6ug/ml, EGF5 ~ 25ng/ml, bFGF10 ~ 18ng/ml, ox pituitary gland extract (BPE) 1 ~ 3mg/L, stem cell factor (SCF) 5 ~ 40ng/ml, hydrocortisone 0.3 μ g/ml, commercial substratum DMEM and commercial substratum F12 (1: 1) constant volume are to 500ml.PH7.2～7.4。
Preparation nutrient solution C: inactivated fetal bovine serum 60ml, Transferrins,iron complexes 6 ~ 17 μ g/ml, adenosine 10 ~ 25mg/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, Regular Insulin 4 ~ 6 μ g/ml, EGF5 ~ 25ng/ml, bFGF10 ~ 18ng/ml, ox pituitary gland extract (BPE) 2 ~ 3mg/L, stem cell factor (SCF) 15 ~ 40ng/ml, hydrocortisone 0.3 μ g/ml, commercial substratum DMEM and commercial substratum F12 (1: 1) constant volume are to 500ml.PH7.2～7.4。
2. prepare the high method intending cells in vivo epimatrix, comprise the following steps: a) draw materials and skin degerming process; B) de-cell process; Preferably, also comprise skin sterilization or warp being taken off cell process further and carry out low temperature, dehydration, irradiation sterilization process further; More preferably step b) method for removing cells be selected from cold enzyme Crosslink bond type, enzyme-nonionogenic tenside-complexing agent integrated process, complexing agent salt adding-anion surfactant method or pancreatin associating EDTA crosslinked fluid method.
3. method described in claim 2, wherein cold enzyme Crosslink bond type is: add the cold 12 ~ 48h that disappears of 0.1 ~ 0.25% proteolytic enzyme ice bath.With containing 0.25% glutaraldehyde phosphate buffer solution, PH is between 7.20 ~ 7.40, and crosslinked 4 ~ 6h, ultrapure water or water for injection rinse 8 ~ 10 times.
4. method described in claim 2, wherein enzyme-nonionogenic tenside-complexing agent integrated process is: 0.1 ~ 0.25% neutral protease and 0.01 ~ 0.02%EDTA, TritonX-100 (0.3 ~ 0.6%) solution, acts on 24 ~ 48h under room temperature.
5. method described in claim 2, its complexing agent salt adding-anion surfactant method is: 0.01 ~ 0.02%EDTA is containing 0.6 ~ 0.8mol/L sodium chloride solution, 12 ~ 24h is acted on, rear use (0.2 ~ 0.5%SDS solution acts on 30 ~ 60min under room temperature) at 37 DEG C.
6. method described in claim 2, wherein pancreatin associating EDTA crosslinked fluid is: 0.25 ~ 0.40% trypsinase and 0.02 ~ 0.04%EDTA (1: 2), 37 DEG C of rapid digestion 10 ~ 60min.Crosslinked 4 ~ 6h in crosslinked fluid.Rinse 8 ~ 10 times with ultrapure water or water for injection after crosslinked.
7. the height prepared by either method described in claim 2-6 intends cells in vivo epimatrix.
8. the height that prepared by either method described in claim 2-6 intends cells in vivo epimatrix or height according to claim 7 intends the purposes of cells in vivo epimatrix in screening skin progenitor cell.
9. utilize the substratum described in claim 1 to combine and the high method intended the screening of cells in vivo epimatrix and cultivate dermal multipotent stem cells according to claim 7, comprising:
A) prepare dermal multipotent stem cells suspension: draw materials, digestion, stop digestion with nutrient solution A according to claim 1, peel off epidermis and collect skin graft, put in Digestive system preparation B or C, collecting cell suspension.Nutrient solution A nutrient solution is added after centrifugal;
B) screening of dermal multipotent stem cells and cultivation: height according to claim 7 is intended cells in vivo epimatrix and adds nutrient solution B according to claim 1, add the cell suspension that step a) is prepared, cultivate, cleaning, targeted dermis multipotential stem cell is adherent adheres to high plan cells in vivo epimatrix, adds nutrient solution C according to claim 1 and carries out amplification cultivation;
C) enrichment Secondary Culture is digested: digestion, adds nutrient solution C according to claim 1 and carry out amplification cultivation after centrifugal.
Preferably, the process of immunologic escape method draw materials before skin or obtain cell, immunologic escape method can be rays method, low temperature freeze-thaw method
Accompanying drawing explanation
Fig. 1 height intends cells in vivo epimatrix preparation flow
Fig. 2 cell screening is cultivated
One, high plan cells in vivo epimatrix kind
(skin related to is organ donation, and in peritomize skin and medical treatment process, skin-grafting is got skin and discarded skin histology)
1.1 is characterized in that: for the current situation of the technology of the present invention, the object of this invention is to provide skin corium in a kind of high plan body to attach for screening as extracellular matrix, the method of adult or embryo skin dermal multipotent stem cells screening and separating and vitro culture, and the high purity dermal multipotent stem cells making acquisition.
1.2 is characterized in that: for the current situation of the technology of the present invention, the object of this invention is to provide full thickness skin in a kind of high plan body to attach for screening as extracellular matrix, the method of adult or embryo skin skin progenitor cell screening and separating and vitro culture, and the high purity skin progenitor cell making acquisition.Skin cells comprises: (the attached relevant stem cell of dermal multipotent stem cells, hair follicle stem cells, epidermal stem cells and other appendages of skin and skin relevant cell).
The method of this screening and separating and vitro culture, the dermal multipotent stem cells cell of acquisition overcomes the defect of above traditional seven kinds of methods.
Invention belongs to biological adult (fetus) stem cells technical field, relates to the separation and ientification method of dermal multipotent stem cells.Method feature comprises: consubstantiality epidermis, corium, holostrome take off the preparation of Cuticle of cell substrate; The separation of consubstantiality dermal cell; Utilize high screening and the cultivation of intending attaching substratum dermal multipotent stem cells in body.Subculture has been stablized in vitro more than 20 ~ 30 (generation) at present by this method, the acellular poison of this cell is confirmed through experiment in vivo and vitro, there is strong multiplication capacity, and the holostrome differentiation skin corium structure that can form maturation is about skin progenitor cell plays immeasurable effect in scientific research, teaching and clinical application, breeds huge academic direction and Social benefit and economic benefit simultaneously.The academic Foundation of other stem cells of China is advanced by this kind of theoretical method basis.
Two, high cells in vivo matrix of intending is formed:
Contain multiple collagen by analysis and comprise IV type, wherein type i collagen content maximum (ratio of I and type III collagen is 10: 1), also retains complete basement membrane structure simultaneously.
Three, height is intended cells in vivo matrix substrates porosity and is sticked surface characteristic:
High plan substrate electron microscopic observation, the basilar membrane pore diameter measuring the substrate tissue regeneration that epidermis sticks is 32 ~ 145um, promotes that sticking dermal tissue regeneration substrate basilar membrane porous pore diameter is 72 ~ 191 μm.This porosity purchase the space built and stick all favourable Stem Cells adhesion apposition growth in surface, propagation, differentiation.
By above preparation method; Effectively remain the microcosmic framework of skin cells epimatrix and complete basement membrane structure, its main component comprises the insoluble matrix compositions such as each Collagen Type VI, elastin, protein-polysaccharide and glycosaminoglycan, can be the adhere fast such as corium stem cell, epidermal stem cells, propagation expansion strong support is provided.Therefore, high plan substrate is the solution of current optimal organization engineering skin stem cell screening.
Four, skin progenitor cell height intends the concrete implementation step of cells in vivo matrix composition and method:
One, following two step kind methods are comprised:
Step one: skin degerming treating processes: get donor dermal and comprise following (embryo skin, adult foreskin outside plate, scalp, armpit skin and body skin) partial thickness skin containing epidermis dermis structure, cut into tissue block and be immersed in normal saline dilution containing 10 ~ 15min in 0.05 ~ 0.1% benzalkonium bromide solution, disinfect, with stroke-physiological saline solution cleaning and removing residual Morpan BB repeatedly.
Step 2: low temperature-60 ~-80 DEG C of lyophilizes, vacuum tightness reaches 20 ~ 110pa, sloughs tissue block more than 90 ~ 95% moisture, takes out sealing and vacuum packaging, through irradiation 25 ~ 60KGY doses of sterilization.Whole product can be preserved as long as five years at room temperature.Start and only need soak 37 DEG C, PBS liquid or below described nutritive medium recovery 15 ~ 30min can apply, and it is better that immersion extends to 10 ~ 12h effect.Use rear and the de-cell process of cell rinsing liquid (mentioning applicable de-enchylema see corresponding in lower method) should be spent, again through the feature of said process immortality Reusability.
1: step 2 embodiment:
Described in above-mentioned mentioned de-enchylema is prepared as follows:
Two, method:
Case method 1: skin graft adds the cold 12 ~ 48h that disappears of 0.1 ~ 0.25% proteolytic enzyme ice bath after treatment.Between 7.20 ~ 7.40, tissue block is rinsed 3 ~ 6 times with crosslinked fluid with regulating PH containing 0.25% glutaraldehyde phosphate buffer solution, finally put into the crosslinked 4 ~ 6h of crosslinked fluid, terminate rear ultrapure water (or water for injection) and repeatedly rinse the residual glutaraldehyde of 8 ~ 10 removals, can freeze-drying and dehydrating encapsulation be carried out.
1.1: case method 1 embodiment:
Method one feature: linking agent can effectively connective tissue protein not capacitive be cross-linked framework, strengthen the anti-degradation property of substrate, keep substrate complete, protease treatment substrate can make its soft wilfulness strengthen.
Skin epidermis includes four-layer structure, and each confluent monolayer cells amount is 10 ~ 30%, and wherein malpighian layer is called that basal cell layer is the attachment Differentiation place that cell enlivens the most, has and reaches 9 ~ 15 layers more than; Granular layer structure contains a large amount of gaps nonwoven fabric from filaments, and cutinized layer is many in netted braided, the three-dimensional complicated capable structure of space IPN, and external supporting material is difficult to simulation and imitates.So class substrates is best suited for the ideal microenvironment place needed for cell adhesion proliferate differentiation.
Case method 2: enzyme-nonionogenic tenside-complexing agent integrated process
0.1 ~ 0.25%DisPase neutral protease and 0.01 ~ 0.02%EDTA simultaneous digestion, neutral protease acts on basilar membrane, optionally decompose fibronectin and IV Collagen Type VI (acting on 48h at 4 DEG C), then applying nonionic surface active agent makes cytolysis destroy TritonX-100 (Triton X-100) (0.3 ~ 0.6% solution, 24 ~ 48h is acted under room temperature) form mixture with the lipid binding such as phosphatide in microbial film and be dissolved in solution, oleophylic cardinal extremity simultaneously in TritonX-100 also can with cell outer membrane protein decohesion microbial film, thus reach de-and abandon cytosis.
After digestion, alternative stripping epidermis dermis, carries out glutaraldehyde cross-linking step through method 1, can carry out freeze-drying and dehydrating encapsulation.
2.1: case method 2 embodiment:
Case method 3: complexing agent salt adding-anion surfactant method
(0.01 ~ 0.02%EDTA is containing 0.6 ~ 0.8mol/L sodium chloride solution to utilize high permeating sodium chloride solution, 12 ~ 24h is acted at 37 DEG C) hemidesmosome of anchor-shaped filament and epidermal basal cell is separated, thus complete removal epidermis, rupture of membranes agent sodium laurylsulfonate (0.2 ~ 0.5%SDS solution acts on 30 ~ 60min under room temperature) is used cellular constituent to be removed from corium again.
Above step alternative peels off epidermis dermis, retains holostrome and carries out glutaraldehyde cross-linking step through method 1, can carry out freeze-drying and dehydrating encapsulation.
3.1: case method 3 embodiment:
Case method 4: by 0.25 ~ 0.40% trypsinase and 0.02 ~ 0.04%EDTA (1: 2) mixed solution simultaneous digestion tissue block, 37 DEG C, rapid digestion 10 ~ 60min, rinsing takes off cell repeatedly, finally put into the crosslinked 4 ~ 6h of crosslinked fluid, terminate rear ultrapure water (or water for injection) and repeatedly rinse the residual glutaraldehyde of 8 ~ 10 removals, can freeze-drying and dehydrating encapsulation be carried out.
4.1: case method 4 embodiment:
Above method is all capable of being combined prepares high plan described in cells in vivo epimatrix: 1.1,1.2 carry out screening stem cell.
The obtained slightly difference of aforesaid method, cost had time different but all can effectively make cellular constituent be eliminated, the structural integrity of matrix is retained, content containing elastin, keratan sulfate, laminin, IV Collagen Type VI, fibronectin, desmin, HLA-DR is more, and basement membrane structure composition all can completely retain.
Seed stem cell for tack provides favourable microenvironment, and make it express, grow, breed, differentiation etc. is played and important, and is better than above-mentioned 7 kinds of conventional screening assays irreplaceable height simulation attachment state space.We are referred to as " the black edatope of cell seeding ".
High plan cells in vivo epimatrix/Screening matrix dermal multipotent stem cells culture method
Five, skin is drawn materials screening:
Human stem cell screening position comprises, fetal skin, foreskin outside plate, scalp, armpit area skin.
Draw materials in high cells in vivo epimatrix position of intending: fetal skin, foreskin outside plate, scalp, armpit area skin, other area skin.
Fully soak 3 ~ 5min with the PBS containing microbiotic (penicillin 80 ~ 100u/ml and 80 ~ 100 μ g/ml Streptomycin sulphates) when receiving, finishing sample removes subcutis as far as possible.
Six, skin progenitor cell screening and culturing step
Because stem cell has stronger adhesivity to basilar membrane, more faster than other cell type to the adhesion speed of cell extracellular matrix, so utilize this kind of characteristic to carry out cultivation screening.
Seven, dermal multipotent stem cells screening and culturing claimed method:
1, nutrient solution preparation:
Preparation nutrient solution A: inactivated fetal bovine serum 40 ~ 60ml, Transferrins,iron complexes 5 ~ 15 μ g/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, vitamins C 1 ~ 3 μ g/ml, Regular Insulin 2 ~ 4 μ g/ml, cholera mycin 2.5 ~ 4.5u/L, EGF5 ~ 25ng/ml, hydrocortisone 0.4 μ g/ml, commercial substratum DMEM/F12 (3: 1) constant volume are to 500ml.
A.1: preparation nutrient solution A embodiment
Preparation nutrient solution B: inactivated fetal bovine serum 80ml, Transferrins,iron complexes 6 ~ 17 μ g/ml, adenosine 10 ~ 25mg/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, cholera mycin 2.5 ~ 3.5u/L, Regular Insulin 4 ~ 6 μ g/ml, EGF5 ~ 25ng/ml, bFGF10 ~ 18ng/ml, ox pituitary gland extract (BPE) 1 ~ 3mg/L, stem cell factor (SCF) 5 ~ 40ng/ml, hydrocortisone 0.3 μ g/ml, commercial substratum DMEM and commercial substratum F12 (1: 1) constant volume are to 500ml.PH7.2～7.4。
B.1: preparation nutrient solution B embodiment
Preparation nutrient solution C: inactivated fetal bovine serum 60ml, Transferrins,iron complexes 6 ~ 17 μ g/ml, adenosine 10 ~ 25mg/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, Regular Insulin 4 ~ 6 μ g/ml, EGF5 ~ 25ng/ml, bFGF10 ~ 18ng/ml, ox pituitary gland extract (BPE) 2 ~ 3mg/L, stem cell factor (SCF) 15 ~ 40ng/ml, hydrocortisone 0.3 μ g/ml, commercial substratum DMEM and commercial substratum F12 (1: 1) constant volume are to 500ml.PH7.2～7.4。
C.1: preparation nutrient solution C embodiment
Illustrate that this formula is original cuiture, building is stablize follow-up resuming for reducing foetal calf serum usage quantity, cultivates domestication cell non-serum and cultivates habit.Other carry out descending domestication and cultivate as Regular Insulin, hydrocortisone are corresponding.Regulate EGF, bEGF consumption to make it break up when building tissue engineering epidermis layer and set up dermis.Other basic components are constant.
2, Digestive system preparation method:
Digestive system preparation A: containing solute neutral protease 0.1% without Ca
2+, Mg
2+, serum-free medium is solvent, obtain solution.
Digestive system preparation B: containing solute 0.15% pancreatin and 0.01%EDTA type i collagen enzyme 0.1% collagenase (1: 1: 1) without Ca
2 +, Mg
2+, serum-free medium is solvent, obtain solution.
3, skin and the preparation of screening cell freeze thawing conserving liquid:
Freeze proof solute component comprises: adenine phosphate 5 ~ 15 μ g/ml, Catergen ~ 6 μ g/ml, chondroitin sulfate 3 ~ 6%, polyoxyethylene glycol 4ml, deactivation calf serum 10 ~ 15%, glycerine 20%, N.F,USP MANNITOL 3ml, cytochalasin 2.7 μ g/ml, dimethyl sulfoxide (DMSO) (DMSO) 10%, conserving liquid with DMEM/F12 (1: 1) 46 ~ 50% for antifreeze solution prepared by solvent.PH controls 7.3 ~ 7.4,0.22 μm of micropore Entkeimung.
3.1:3 skin and screening cell freeze thawing conserving liquid prepare embodiment:
Illustrate, it is characterized in that: this refrigerating fulid not only, formulating of recipe active by freezing long-term preservation skin and skin cells can also have and suppress Langerhans cell present function and play the immunogenicity that can reduce skin.
4, skin sample irradiates low-temperature storage immunologic escape antigenicity cellular processes:
3.1 immunologic escape method rays methods: epidermis sample disposal: get the skin described in five, are immersed in nutrient solution A and irradiate 10 ~ 30min through UV-B/C (UVB middle-ultraviolet lamp, UVC far ultraviolet rays yue).
Illustrate: uviolizing, gamma-rays can reduce immunological rejection, uviolizing effectively can reduce this cell quantity of Netac's Chinese, significantly suppress the antigen presentation capability of Langerhans cell.
At present disclose to irradiate how to affect APC function, ray can affect epidermic cell produce as some immunosuppression things such as the uridylic acid (cis urocanic acid) in IL-10, stratum corneum with this reduce transplanting the immunological rejection effect that produces.Clinical treatment is approved by extensive scholar doctor through postradiation skin graft survival time significant prolongation.
3.2 immunologic escape method freeze-thaw methods:
Epidermis sample disposal: get the skin described in five, soaks skin freeze thawing conserving liquid through anti frozen liquid process, is placed on 12 ~ 48h in-40 ,-60 ,-90 ,-100 ,-196 DEG C of environment respectively.
Illustrate: to express change not obvious for Langerhans cell cytolemma HLA-DR after cryopreservation, but its costimulatory molecules CD86 significantly reduces, and transplants such skin, accepted the time by acceptor and obviously extend.Low temperature makes the disappearance of the function limitation of Langerhans cell, cytoplasmic process, quantity minimizing, smaller volume, shows that these temperature spots can obviously reduce transplant rejection phenomenon through test mice transplant experiment simultaneously, and it is more obvious that trend presents temperature lower immunologic escape phenomenon.
7, dermal multipotent stem cells screening step method:
Step 1, get skin cells screening in be separated skin corium skin histology sample (get the skin histology sample of 0.5 × 1.0cm, 1 × 2cm size or other specification, to rinse 3 ~ 6 times containing antibiotic PBS, put 4 DEG C of cold digestion 12 ~ 18h in Digestive system preparation A and take out sample, peel off epidermis, skin corium), to rinse 3 ~ 6 times containing antibiotic PBS, by corium skin graft, put in Digestive system preparation B.37 DEG C of 40 ~ 60min digestion, stop digestion with preparation nutrient solution B, the centrifugal 5 ~ 10min of 600 ~ 1000r/min, abandons or adopts supernatant liquor, and add preparation nutrient solution A, cell concn is adjusted to 1 × 10
3~ 1 × 10
5/ ml.
Step 2, get high cells in vivo epimatrix of intending and select 1.1, also optional standby 1.2, rinse 3 times with containing antibiotic PBS, then rinse 3 times with preparing nutrient solution B, in 37 DEG C, be immersed in recovery 10 ~ 12h in nutrient solution B for subsequent use.
The screening of step 3, dermal multipotent stem cells and cultivation: get ready 1.1 and put into plate and add preparation nutrient solution B, add cell concn 1 × 10
3~ 1 × 10
4/ ml dermal cell suspension, 37 DEG C, gas phase 5%C0
2incubator is cultivated 4 ~ 6h and is taken out, and taking-up transfer 1.1, PBS or nutrient solution B clean 3 ~ 6 times, and targeted dermis multipotential stem cell is adherent to adhere on 1.1.Change ware and add preparation nutrient solution B cultivation, rear every 2 ~ 4d changes liquid and once continues amplification cultivation.
Step 4, digestion enrichment Secondary Culture:
Above-mentioned dermal multipotent stem cells is after amplification, and add Digestive system preparation B and digest 1.1 matrix, 4 DEG C of digestion 24h, nutrient solution B stop digestion; Suction pipe is is fully blown and beaten, and cross the cell sieve in 40 μm of apertures, collect filtrate, 4 DEG C leave standstill 20 ~ 30min; Then, with the centrifugation 10min of 800 ~ 1000r/min.Abandon supernatant liquor, add the nutrient solution C of preparation, re-suspended cell, with 1 ~ 3 × 10
6the density transfer of/ml is cultivated containing in trophoblastic ware, puts 37 DEG C, gas phase 5%CO
2incubator is cultivated, and every 2 ~ 4d changes nutrient solution C processed and once continues amplification cultivation.
The qualification of the biological characteristics of step 5, corium stem cell
Get the 3rd generation attached cell, with 5 × 10
5/ hole is inoculated in culturing bottle, continue as stated above to cultivate, observation of cell growing state under inverted microscope, respectively at the 1st, 3,6,9,12,15,18d Trypan Blue living cell counting, draw growth curve, get 1,3,6d culturing cell does fluidic cell cycle analysis.
Step 6, immunohistochemical method are examined:
Above cultural method carries out difference detected result:
Dermal multipotent stem cells have hair-fields and without the corium of hair-fields in all have distribution, not yet find the surface marker of dermal multipotent stem cells at present.Get 3d attached cell, make it grow on the cover slip, take out after 1d, discard nutrient solution, PBS liquid fine laundering 3 times, 4% paraformaldehyde is fixed.
Operation steps is carried out according to test kit specification sheets:
Detect the expression of vimentin, nestin, CD34, CD90, CD59, CD44, VIII factor, CK19: vimentin primary antibodie is the monoclonal antibody of mouse anti human, the monoclonal antibody that CD34, CD90, CD59, CD44, nestin, VIII Summing Factor CK19 primary antibodie is behaved.Working concentration is 1: 100.
Measurement result: cell surface vimentin (vimentin), CD34, CD90, CD59, CD44 express the positive, Cyfra21-1 (cytoKeratin19), VIII Summing Factor nidogen (nestin) are expressed negative.Epidermal stem cells and vascular endothelial cell possibility can be got rid of.
Stream type cell analyzer: flow cytometer cell cycle analysis shows, cell (the G pre-synthesis phase of vitro culture primary DNA
0/ G
1phase) be 87 ~ 89%, DNA synthesis phase cell (s phase) be 11-12%.
Conclusion: high plan obtains dermal multipotent stem cells in the dermal tissue of cells in vivo epimatrix 1.1 and 1.2 sieve method enrichment.
After primary inoculation, 6h occurs that adherent behavior 24 ~ 30h starts a large amount of attached cell is on a small quantity cloning growth propagation phenomenon, 3 ~ 6d just can enter cell log vegetative period, under microscope, stem cell is cultivated and is good at Fusoid cells, in many trilaterals, proliferating clones is obviously accelerated, after passing for 2 generations just there is adherent propagation phenomenon in 10 ~ 28h stem cell, cloning growth spherical in shape can adopt low density serial dilution, to obtain the multipotential stem cell clone that can increase.Within 8 ~ 14 days, enter plateau, Secondary Culture 20 ~ 30 generation passage capacity can be kept.
To sum up dermal multipotent stem cells through immunohistochemical method qualification, on the basis of quick wall attaching, subculture in vitro separately multiplication capacity is strong, the cell obtained is targeted dermis multipotential stem cell.
What eight, clinical treatment level dermal multipotent stem cells was invented has the following advantages:
The invention discloses the cultivation of skin progenitor cell, screening, amplification technique, these bottlenecks are biology stem cell field study hotspot and difficult point always, utilize the remarkable adhesion properties of basilar membrane to carry out separation and purification at present, adopt dimensional culture amplification means to obtain.
This invention is applicable to relying on the adherent type cell of amplification and provides three-dimensional high to be intended screening that cells in vivo epimatrix system carries out target cell level and is separated.
The invention belongs in high analogue body and attach environment, the novel culture technique of biomass cells of vitro culture adult (embryo skin) stem cell.It is characterized in that: cell matrix substrate is that donor takes off Cuticle of cell, corium is the best preparation method of sticking place screening stem cell of matrix substrates screening; Corresponding epidermis dermis stem cell height simulation substrate place environment sticks screening and culturing targeted stem cells.With the stem cell that the method obtains, there is high passage capacity, high proliferation ability, and differentiation holostrome corium cortex construction can be formed in vitro under environment, this method has more Scientific Research and Teaching clinical application than traditional stem cell screening and further investigation stem cell growth proliferation and differentiation provides immeasurable scientific research learning value, start external height and intend new era that in body, adherent attachment is cultivated, this method proposes as to initiate both at home and abroad.
By the screening of this high target pattern, the how safe adaptive immune of conjunctive tissue engineering immunogenicity cell is escaped, and extend transplant time and increase organizational project clinical application, wound healing and dermatosis provide the solution of absolute predominance.
1, organization engineering skin; Consubstantiality-Gao intends cells in vivo epimatrix, and it is that current any method is not replaced that matrix attachment in-vitro screening method carries out the microenvironment consistence of screening with in body to seed dermal multipotent stem cells, and preparation simply can Reusability; Build world's the first containing dermal multipotent stem cells all layers of skin used by tissue engineering basis;
2, high specificity, by immunohistochemical methods detection, transmission electron microscope observing and flow cytomery, result shows that skin progenitor cell purity of the present invention is high;
3, the application in trauma repair, in gene studies, beauty and shaping reparation, oral disease, dermatological field;
4, stem cell scientific research value: the cytophyletic research of dermal multipotent stem cells, further investigated research Stem Cells adhesion, the Scientific basis researchs such as growth, propagation, differentiation, Immune expression;
5, the method can be the regeneration of other organ vitro culture and provides good scientific research theoretical basis.
6, the mass-producing industrialization preparation amplification of dermal multipotent stem cells
Reference:
[1] Li Aoliao burns [M]. Shanghai: Shanghai science tech publishing house, 2001.
[2] Shi Jixiang, Liao Zhenjiang, Fang Peiyao chief editor. burn treatment [M]. Zhejiang: Zhejiang Science Press, 2006.
[3] Chen Yisheng, Shi Jingquan chief editor. Burn Pathology [M]. Chongqing: Chongqing press, 1993.
[4] Si Tuzhenqiang, Wu Junzheng chief editor. cell cultures. [M]. world book publishing company, 1996.
[5] Hu Min chief editor. human tissue engineering. [M]. and Beijing. People's Medical Officer Press, 2006.
[6] D.L. Spector, R.D. Ge Deman, L.A. Lay mattress ten thousand moral, Huang Peitang translates. cell experiment guide [M]. and Beijing: Science Press, 2001.
[7] Zhao Chunhua chief editor. stem cell principle, technology and clinical. [M]. and Beijing. modern biotechnology and medical sci-tech publishing centre, [M] .2006.
[8]Robert?Lanza，，John?Gearhart，Brigid?Hogan.Essentials?of?Stem?Cell?Biology[M].AMSTERDAM：ELSEVIER?ACADEVIER?PRESS，2006.
[9]Ghadially?R.Epidermal?stem?cell.[J].AdvDermatol，2005，21：335.
[10]Taylor?G，Michael?S，Lehrer?P?J，eL.?aL.?Involvement?follicular?stem?cells?in?Foming?not?only?the?follicle?but?also?the?epidermis[J].Cell，2000，1?102：451.
[11]Yang?A，Kaghad?M，Caput?D，et?al.On?the?shoulders?of?giants：p63，p73?and?the?rise?of?p53[J].Trends?Geaet，2002，18(2)：195.
[12]Kim?DS，Cho?HJ，Choi?HR，et?al.Isolation?of?human?epidermal?stem?cells?by?adherence?and?the?reconstruction?of?skin?equivalents.Cell?Mol?Life?Sci2004；61(21)：2774-1781.
[13]Jones?P?H.Watt?F?M.Separation?of?human?epidermal?stem?cells?from?transit?amplifying?cells?on?the?bas?is?of?differences?in?in-tegrin?function?and?expression[J].Cell，1993，73(4)：713-724.
[14]Peneg，im?G，Dellambra?E，Golisano?O，et?al.P63?identifies?keratinocyte?stem?cells[J].PNAS，2001，98(6)：3156.
[15]Albert?M?R，Forster?R?A，Vogel?JC.Murine?epidemrallabel-retaining?cells?isolated?by?flow?cytometry?do?not?express?the?stem?cell?markers?CD34，Sca-1，or?Flk-1[J].J?Invest?Dermatol，2001，117(4)：943-948.
[16]Medina?RJ，Kataok?K，Tskaishi?M，et?al.Isolation?of?EpithelialStem?Cells?From?Dermis?by?a?Three-Dimensional?Culture?System.J?CellBiochem2006；98(1)：174-184.
[17]Michel?M，Torok?N，Godbout?MJ，et?al.Keratin?19?as?abiochemical?marker?of?skin?stem?cells?in?vivo?and?in?vitro：keratin?l9?expressing?cells?are?differentially?localized?in?function?of?anatomic?sites，and?their?number?varies?with?donor?age?and?culturestage.Cell?Sci1996；109：1017-1028.
[18]Trempus?CS，Morris?RJ，Bortner?C?D，et?la.Enirch-ment?for?living?murine?keratinocytes?from?the?hair?follicle?bulge?with?the?cell?surface?markerCD34[J].J?Invest?Dermatol，2003，120(4)：501-511.
[19]Lyle?S，Christofidou?SM，Liu?Y，et?al.Human?hair?folliclebulge?cells?are?biochemically?distinct?and?possess?an?epithelial?stemcell?phenotype.J?Investig?Dermatol?Symp?Proc?1999；4(3)：296-301.
[20]Webb?A，Lia，Kaur?P.Location?and?phenotyPe?of?human?a-dult?keratinocyte?stem?cells?of?the?skin?[J].Differentiation，2004，72(8)：387-395.
[21]Poblet?E，Jimenez?F，GodinezJ?M，et?al.The?immunohis-tochemical?expression?of?CD-34?in?human?hair?follicles：a?compar-ative?study?with?the?bulge?marker?CK15[J].Clin?Exp?Dermatol，2006，31(6)：807-812.
[22]Toma?JG，AKhavan?M，Femandes?KJ，Bamabe-Heider?F，Sadikot?A，Kaplan?DR，Miller?FD(2001).Isolation?of?multipotent?adult?stem?cells?from?the?demis?of?mammalian?skin.Nature?Cell?Biology.2001；60(43)：121.1.24-926
[23]Karl?JK，McKenzieIA，Mill?P，et?al.A?dermla?niche?for?multiportent?adult?skin-derived?precursor?cels.Nat?Cell?Biol，2004，6：1082-1093.
[24]YoungHE，Steele?TA，Bray?RA，Hudson?J，Floyd?JA，Hawklns?K，Thomas?K，AnstinT，Edwards?C，Cuzzort?J，Duenzl?M，Lueas?PA，BlackAC?Jr.Human?reserve?Pluripptent?mesenchymal?stem?cells?are?Present?in?the?connective?tissues?of?skeletal?Musele?and?dermis?derived?from?fetal，adult，and?geriatrie?donors.Anat?Rec，2001；264(1)：51-62
[25]YU?H，FANG?D，KUMAR?S?M，et?al.Isolation?of?a?novel?popu-lation?of?multipotent?adult?stem?cells?from?human?hair?follicles[J].Am?J?Pathol，2006，168(6)：1879-1888.
[26]TOMAJG，AKHAVAN?M，FERNANDESK?J，et?al?Isolation?of?multipotent?adult?stem?cells?from?the?dermis?of?mammalian?skin[J].Nat?Cell?Biol，2001，3(9)：778-784.
[27]Zhu?N.(2009)PROGRESS&OPPORTUNITIES-Skin?Banking?and?Tissue?Engineering?of?Skin.Invited?lecture?at?the?15th?Annual?Conference?of?the?Life?Science?Society?for?Chinese?Bioscientists?in?the?UK.Sept?2009，London，England.
[28]Zhu?N.(2009)Latest?Developments?in?Treatment?of?Burns?and?Chronic?Wounds?in?Europe-Clinical?Applications?of?Tissue?Engineered?Skin.Invited?lecture?at?the?Annual?Conference?of?the?Chinese?Burns?Surgery?Association.June?2009，Xian?China.
[29]Zhu?N，Warner?RM，Simpson?C，Glover?M，Kelly?J，Fraser?S，Brotherson?TM，Ralston?DR，MacNeil?S(2007)Treatment?of?Burns?and?Chronic?Wounds?Using?A?New?Chemically?Defined?Carrier?for?Delivery?of?Autologous?Keratinocytes.Presented?at?the?European?Tissue?Repair?Society?and?European?Wound?Management?Association?Conference.2-4?May?2007，Glasgow，Scotland.
[30] Zhu N. (2006) skin tissue engineering and stem-cell therapy are in progress (Invited lecture). the international micro-shaping in the Taibei and stem-cell therapy conference .2006 in October China. and the Taibei.
[31]Zhu?N，Warner?RM，Simpson?C，Glover?M，Kelly?J，Fraser?S，Brotherson?TM，Ralston?DR，MacNeil?S(2005)Treatment?of?Burns?and?Chronic?Wounds?Using?a?New?Cell?Transfer?Dressing?for?Delivery?of?Autologous?Keratinocytes.European?Journal?of?Plastic?Surgery.28，319-330.ISSN：0930-343X(print?vetsion)，ISSN：1435-0130(electronic?version).
[32]Zhu?N.(2012)Progress?of?TGF-βFamily?and?Fetal?Wound?Healing.Invited?lecture?at?the?Annual?Scientific?Conference?of?the?Craniofacial?Society?of?Great?Britain?and?Ireland.April?2012，Bristol，England.
[33] country of the Ministry of Science and Technology of Zhu Ning Wen Zhonghua people's republic high-tech research evolutionary operation(EVOP) " preparation of cellular therapy product clinical grade skin cells bio-reactor mass-producing serum-free and high-performance bio carrier cell transplant key technology research " (863 Program) problem embodiment prospectus [M], 2014-2016.
[34] serum-free medium and compound method granted patent thereof that contain activin A are produced in the industrialization of Zhu Ningwen bioreactor tissue engineering active artificial skin
Claims (9)
1. one kind is combined for the substratum screening and cultivate dermal multipotent stem cells,
Preparation nutrient solution A: inactivated fetal bovine serum 40 ~ 60ml, Transferrins,iron complexes 5 ~ 15 μ g/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, vitamins C 1 ~ 3 μ g/ml, Regular Insulin 2 ~ 4 μ g/ml, cholera mycin 2.5 ~ 4.5u/L, vitamins C 1 ~ 3 μ g/ml, EGF5 ~ 25ng/ml, hydrocortisone 0.4 μ g/ml, commercial substratum DMEM/F12 (3: 1) constant volume are to 500ml.
Preparation nutrient solution B: inactivated fetal bovine serum 80ml, Transferrins,iron complexes 6 ~ 17 μ g/ml, adenosine 10 ~ 25mg/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, cholera mycin 2.5 ~ 3.5u/L, Regular Insulin 4 ~ 6 μ g/ml, EGF5 ~ 25ng/ml, bFGF10 ~ 18ng/ml, ox pituitary gland extract (BPE) 1 ~ 3mg/L, stem cell factor (SCF) 5 ~ 40ng/ml, hydrocortisone 0.3 μ g/ml, commercial substratum DMEM and commercial substratum F12 (1: 1) constant volume are to 500ml.PH7.2～7.4。
Preparation nutrient solution C: inactivated fetal bovine serum 60ml, Transferrins,iron complexes 6 ~ 17 μ g/ml, adenosine 10 ~ 25mg/ml, adenine phosphate 0.5 ~ 1 × 10
-4/ L, Regular Insulin 4 ~ 6ug/ml, EGF5 ~ 25ng/ml, bFGF10 ~ 18ng/ml, ox pituitary gland extract (BPE) 2 ~ 3mg/L, stem cell factor (SCF) 15 ~ 40ng/ml, hydrocortisone 0.3 μ g/ml, commercial substratum DMEM and commercial substratum F12 (1: 1) constant volume are to 500ml.PH7.2～7.4。
2. prepare the high method intending cells in vivo epimatrix, comprise the following steps: a) draw materials and skin degerming process; B) de-cell process; Preferably, also comprise skin sterilization or warp being taken off cell process further and carry out low temperature, dehydration, irradiation sterilization process further; More preferably step b) method for removing cells be selected from cold enzyme Crosslink bond type, enzyme-nonionogenic tenside-complexing agent integrated process, complexing agent salt adding-anion surfactant method or pancreatin associating EDTA crosslinked fluid method.
3. method described in claim 2, wherein cold enzyme Crosslink bond type is: add the cold 12 ~ 48h that disappears of 0.1 ~ 0.25% proteolytic enzyme ice bath.With containing 0.25% glutaraldehyde phosphate buffer solution, PH is between 7.20 ~ 7.40, and crosslinked 4 ~ 6h, ultrapure water or water for injection rinse 8 ~ 10 times.
4. method described in claim 2, wherein enzyme-nonionogenic tenside-complexing agent integrated process is: 0.1 ~ 0.25% neutral protease and 0.01 ~ 0.02%EDTA, TritonX-100 (0.3 ~ 0.6%) solution, acts on 24 ~ 48h under room temperature.
5. method described in claim 2, its complexing agent salt adding-anion surfactant method is: 0.01 ~ 0.02%EDTA is containing 0.6 ~ 0.8mol/L sodium chloride solution, 12 ~ 24h is acted on, rear use (0.2 ~ 0.5%SDS solution acts on 30 ~ 60min under room temperature) at 37 DEG C.
6. method described in claim 2, wherein pancreatin associating EDTA crosslinked fluid is: 0.25 ~ 0.40% trypsinase and 0.02 ~ 0.04%EDTA (1: 2), 37 DEG C of rapid digestion 10 ~ 60min.Crosslinked 4 ~ 6h in crosslinked fluid.Rinse 8 ~ 10 times with ultrapure water or water for injection after crosslinked.
7. the height prepared by either method described in claim 2-6 intends cells in vivo epimatrix.
8. the height that prepared by either method described in claim 2-6 intends cells in vivo epimatrix or height according to claim 7 intends the purposes of cells in vivo epimatrix in screening skin progenitor cell.
9. utilize the substratum described in claim 1 to combine and the high method intended the screening of cells in vivo epimatrix and cultivate dermal multipotent stem cells according to claim 7, comprising:
A) prepare dermal multipotent stem cells suspension: draw materials, digestion, stop digestion with nutrient solution A according to claim 1, peel off epidermis and collect skin graft, put in Digestive system preparation B or C, collecting cell suspension.Nutrient solution A nutrient solution is added after centrifugal;
B) screening of dermal multipotent stem cells and cultivation: height according to claim 7 is intended cells in vivo epimatrix and adds nutrient solution B according to claim 1, add the cell suspension that step a) is prepared, cultivate, cleaning, targeted dermis multipotential stem cell is adherent adheres to high plan cells in vivo epimatrix, adds nutrient solution C according to claim 1 and carries out amplification cultivation;
C) enrichment Secondary Culture is digested: digestion, adds nutrient solution C according to claim 1 and carry out amplification cultivation after centrifugal.
Preferably, the process of immunologic escape method draw materials before skin or obtain cell, immunologic escape method can be rays method, low temperature freeze-thaw method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410482325.8A CN104263699A (en) | 2014-09-19 | 2014-09-19 | Culture method for large-scale preparation of clinical treatment level dermal multipotent stem cells for cell transplantation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410482325.8A CN104263699A (en) | 2014-09-19 | 2014-09-19 | Culture method for large-scale preparation of clinical treatment level dermal multipotent stem cells for cell transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104263699A true CN104263699A (en) | 2015-01-07 |
Family
ID=52155283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410482325.8A Pending CN104263699A (en) | 2014-09-19 | 2014-09-19 | Culture method for large-scale preparation of clinical treatment level dermal multipotent stem cells for cell transplantation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104263699A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104818247A (en) * | 2015-05-18 | 2015-08-05 | 云南和泽西南生物科技有限公司 | Culture method and application of mesenchymal stem cell |
| CN105238740A (en) * | 2015-11-08 | 2016-01-13 | 复旦大学附属华山医院 | In-vitro screening and culturing method for tissue engineering skin seed epidermal keratinocyte high-simulation in-vivo cell extracellular matrix attachment |
| CN105238739A (en) * | 2015-11-11 | 2016-01-13 | 朱宁文 | Selective culture method for large-scale preparation of human extracellular matrix through melanocytes for clinic treatment level cell therapy |
| CN105255822A (en) * | 2015-11-08 | 2016-01-20 | 复旦大学附属华山医院 | Method for screening and culturing extracellular hair follicle stem cell matrix for clinic treatment level cell therapy |
| CN105647860A (en) * | 2016-03-30 | 2016-06-08 | 王凌仪 | Serum-free in-vitro extraction and preparation method of clinical treatment-grade placental decidua basalis-mesenchymal stem cells (PDB-MSCs) |
| CN105713869A (en) * | 2016-03-30 | 2016-06-29 | 王凌仪 | In-vitro three-dimensional isolated culture and storage method for hCDMSC (human chorion-derived mesenchymal stem cell) for clinical adoptive therapy |
| CN105779384A (en) * | 2016-03-30 | 2016-07-20 | 王凌仪 | Seed cell screening and culturing cryopreservation technical method of human amniotic mesenchymal stem cells for tissue engineering |
| CN105779381A (en) * | 2016-03-30 | 2016-07-20 | 王凌仪 | Clinical treatment grade preparation method used for screening human umbilical cord derived WJ-MSCs (Wharton's jelly mesenchymal stem cells) in large scale by applying extracellular matrices through three-dimensional attachment and for cell treatment |
| CN105820998A (en) * | 2016-03-30 | 2016-08-03 | 王凌仪 | Isolation extraction and culture method for human adipose-derived stem cells (ADSCs) for clinical back-transfusion grade cell therapy |
| CN106318979A (en) * | 2015-02-10 | 2017-01-11 | 黄兵 | Method for inducing transdifferentiation of mesenchymal stem cells into skin stem cells |
| EP3326660A1 (en) | 2016-11-28 | 2018-05-30 | Datt Mediproducts Pvt. Ltd | A ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof |
| CN109395164A (en) * | 2018-11-29 | 2019-03-01 | 四川大学 | A kind of preparation method of the zooblast extracellular matrix materials of desiccation |
| CN110292038A (en) * | 2018-03-23 | 2019-10-01 | 北京世纪劲得生物技术有限公司 | Frozen solution of mescenchymal stem cell and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649998A (en) * | 2002-03-29 | 2005-08-03 | 新加坡眼部研究所 | Method for growth of human conjunctival tissue equivalents for research, clinical ocular surface transplantation and tissue engineering |
| CN102462864A (en) * | 2010-11-12 | 2012-05-23 | 中国辐射防护研究院 | Novel method for constructing tissue engineering skin |
| CN102505005A (en) * | 2011-12-24 | 2012-06-20 | 南方医科大学 | Culture medium for keeping primary airway epithelial cells in physiological state in vivo |
| CN103881970A (en) * | 2014-03-10 | 2014-06-25 | 江苏大学 | Rat dermal mesenchymal stem cell culture method |
-
2014
- 2014-09-19 CN CN201410482325.8A patent/CN104263699A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649998A (en) * | 2002-03-29 | 2005-08-03 | 新加坡眼部研究所 | Method for growth of human conjunctival tissue equivalents for research, clinical ocular surface transplantation and tissue engineering |
| CN102462864A (en) * | 2010-11-12 | 2012-05-23 | 中国辐射防护研究院 | Novel method for constructing tissue engineering skin |
| CN102505005A (en) * | 2011-12-24 | 2012-06-20 | 南方医科大学 | Culture medium for keeping primary airway epithelial cells in physiological state in vivo |
| CN103881970A (en) * | 2014-03-10 | 2014-06-25 | 江苏大学 | Rat dermal mesenchymal stem cell culture method |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106318979B (en) * | 2015-02-10 | 2021-02-19 | 黄兵 | Method for inducing transdifferentiation of mesenchymal stem cells into skin stem cells |
| CN106318979A (en) * | 2015-02-10 | 2017-01-11 | 黄兵 | Method for inducing transdifferentiation of mesenchymal stem cells into skin stem cells |
| CN104818247A (en) * | 2015-05-18 | 2015-08-05 | 云南和泽西南生物科技有限公司 | Culture method and application of mesenchymal stem cell |
| CN104818247B (en) * | 2015-05-18 | 2017-06-16 | 云南和泽西南生物科技有限公司 | The cultural method and purposes of a kind of mescenchymal stem cell |
| CN105238740A (en) * | 2015-11-08 | 2016-01-13 | 复旦大学附属华山医院 | In-vitro screening and culturing method for tissue engineering skin seed epidermal keratinocyte high-simulation in-vivo cell extracellular matrix attachment |
| CN105255822A (en) * | 2015-11-08 | 2016-01-20 | 复旦大学附属华山医院 | Method for screening and culturing extracellular hair follicle stem cell matrix for clinic treatment level cell therapy |
| CN105238739A (en) * | 2015-11-11 | 2016-01-13 | 朱宁文 | Selective culture method for large-scale preparation of human extracellular matrix through melanocytes for clinic treatment level cell therapy |
| CN105820998A (en) * | 2016-03-30 | 2016-08-03 | 王凌仪 | Isolation extraction and culture method for human adipose-derived stem cells (ADSCs) for clinical back-transfusion grade cell therapy |
| CN105779381A (en) * | 2016-03-30 | 2016-07-20 | 王凌仪 | Clinical treatment grade preparation method used for screening human umbilical cord derived WJ-MSCs (Wharton's jelly mesenchymal stem cells) in large scale by applying extracellular matrices through three-dimensional attachment and for cell treatment |
| CN105779384A (en) * | 2016-03-30 | 2016-07-20 | 王凌仪 | Seed cell screening and culturing cryopreservation technical method of human amniotic mesenchymal stem cells for tissue engineering |
| CN105713869A (en) * | 2016-03-30 | 2016-06-29 | 王凌仪 | In-vitro three-dimensional isolated culture and storage method for hCDMSC (human chorion-derived mesenchymal stem cell) for clinical adoptive therapy |
| CN105647860A (en) * | 2016-03-30 | 2016-06-08 | 王凌仪 | Serum-free in-vitro extraction and preparation method of clinical treatment-grade placental decidua basalis-mesenchymal stem cells (PDB-MSCs) |
| EP3326660A1 (en) | 2016-11-28 | 2018-05-30 | Datt Mediproducts Pvt. Ltd | A ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof |
| US10098986B1 (en) | 2016-11-28 | 2018-10-16 | Datt Mediproducts Limited | Ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof |
| US10149924B1 (en) | 2016-11-28 | 2018-12-11 | Datt Mediproducts Limited | Ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof |
| CN110292038A (en) * | 2018-03-23 | 2019-10-01 | 北京世纪劲得生物技术有限公司 | Frozen solution of mescenchymal stem cell and preparation method thereof |
| CN110292038B (en) * | 2018-03-23 | 2021-08-24 | 北京世纪劲得生物技术有限公司 | Freezing protection solution for mesenchymal stem cells and preparation method thereof |
| CN109395164A (en) * | 2018-11-29 | 2019-03-01 | 四川大学 | A kind of preparation method of the zooblast extracellular matrix materials of desiccation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104263699A (en) | Culture method for large-scale preparation of clinical treatment level dermal multipotent stem cells for cell transplantation | |
| CN104312970A (en) | Preparation method of clinical treatment level epidermal stem cell for cell therapy by applying human extracellular matrix screening and mass culture | |
| JP3808900B2 (en) | Biological material composed of a three-dimensional biocompatible and biodegradable matrix comprising an effective culture of bone marrow stem cells partially or fully differentiated into connective tissue cells and a hyaluronic acid derivative | |
| KR100870508B1 (en) | Adipose-derived stem cells and lattices | |
| CN105963785B (en) | Acellular matrix material based on adipose-derived stem cell membrane and preparation method thereof | |
| CN104263698B (en) | Clinical treatment level cell therapy is prepared human cell's epimatrix screening and culturing method with fibroblast scale | |
| CN105255822A (en) | Method for screening and culturing extracellular hair follicle stem cell matrix for clinic treatment level cell therapy | |
| CN105820998A (en) | Isolation extraction and culture method for human adipose-derived stem cells (ADSCs) for clinical back-transfusion grade cell therapy | |
| CN105779381A (en) | Clinical treatment grade preparation method used for screening human umbilical cord derived WJ-MSCs (Wharton's jelly mesenchymal stem cells) in large scale by applying extracellular matrices through three-dimensional attachment and for cell treatment | |
| EA025532B1 (en) | Method for isolation of precursor cells from human umbilical cord | |
| JP4550582B2 (en) | Hair-derived cell culture | |
| RU2433172C2 (en) | Method of obtaining homogenous population of stem cells and its application | |
| CN105647860A (en) | Serum-free in-vitro extraction and preparation method of clinical treatment-grade placental decidua basalis-mesenchymal stem cells (PDB-MSCs) | |
| CN104087551A (en) | Novel method for in-vitro separated culture of human epidermal cells | |
| CN105779384A (en) | Seed cell screening and culturing cryopreservation technical method of human amniotic mesenchymal stem cells for tissue engineering | |
| CN105238739A (en) | Selective culture method for large-scale preparation of human extracellular matrix through melanocytes for clinic treatment level cell therapy | |
| Ghanavati et al. | Characterization of a three-dimensional organotypic co-culture skin model for epidermal differentiation of rat adipose-derived stem cells | |
| CN103497892A (en) | Cell culture substrate, and preparation method and application thereof | |
| CN107802891A (en) | Organization engineering skin and preparation method thereof | |
| WO2009080794A1 (en) | Method for preparing cell-specific extracellular matrices | |
| CN105238740A (en) | In-vitro screening and culturing method for tissue engineering skin seed epidermal keratinocyte high-simulation in-vivo cell extracellular matrix attachment | |
| CN105713869A (en) | In-vitro three-dimensional isolated culture and storage method for hCDMSC (human chorion-derived mesenchymal stem cell) for clinical adoptive therapy | |
| CN103893831B (en) | A kind of organotypic artificial skin, its preparation method and application | |
| CN101029303B (en) | Substance and method for splitting induced dry-cell to cartilage | |
| RU2272638C1 (en) | Biotransplant, method for its preparing and method for treatment of chronic hepatitis and liver cirrhosis (variants) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 225300 Perrin Road, Taizhou high tech Zone, Jiangsu, China, No. 18 Applicant after: JIANGSU HUAYI CELL TISSUE ENGINEERING CO., LTD. Address before: 225300 R18 research and development building, No.1 pharmaceutical City Road, Taizhou, China, Jiangsu Applicant before: JIANGSU HUAYI CELL TISSUE ENGINEERING CO., LTD. |
|
| COR | Change of bibliographic data | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150107 |
|
| RJ01 | Rejection of invention patent application after publication |